BiomarkersHumans

Continuous Glucose Monitoring Metrics Predict ≥40% EGFR Decline among Adults with Type 1 and Type 2 Diabetes

ADA Scientific Sessions 2026 Abstract

The paper

Tomoki Okuno, Sharon Macwan, Greg Norman,

Donald R. Miller, Peter D. Reaven,

Los Angeles

ADA Scientific Sessions 2026 Abstract · 5 Jun 2026

Presented at ADA Scientific Sessions 2026 · Poster 1902-P

doi.org/10.2337/db26-1902-p

SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
Underweight is linked to higher kidney disease risk in diabetes
Frontiers in Endocrinology · 4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
Metabolic markers jointly link to higher multimorbidity risk
Research Square · 4 Oct 2026